{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:34:51Z","timestamp":1783632891105,"version":"3.55.0"},"reference-count":251,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1210\/er.2018-00166","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T14:04:59Z","timestamp":1543586699000},"page":"558-574","source":"Crossref","is-referenced-by-count":128,"title":["Growth Hormone\u2019s Links to Cancer"],"prefix":"10.1210","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7285-7941","authenticated-orcid":false,"given":"Cesar Luiz","family":"Boguszewski","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Endocrine Division (SEMPR), University Hospital, Federal University of Parana, Curitiba, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5306-0715","authenticated-orcid":false,"given":"Margaret Cristina da Silva","family":"Boguszewski","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Endocrine Division (SEMPR), University Hospital, Federal University of Parana, Curitiba, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2018,11,30]]},"reference":[{"issue":"4","key":"2019041122190634300_B1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/1043-2760(92)90099-M","article-title":"Growth hormone. What is it and what does it do","volume":"3","author":"Lewis","year":"1992","journal-title":"Trends Endocrinol Metab"},{"issue":"5","key":"2019041122190634300_B2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrendo.2018.22","article-title":"Growth hormone\u2014past, present and future","volume":"14","author":"Ranke","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"2019041122190634300_B3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ygcen.2014.11.004","article-title":"Autocrine\/paracrine roles of extrapituitary growth hormone and prolactin in health and disease: an overview","volume":"220","author":"Harvey","year":"2015","journal-title":"Gen Comp Endocrinol"},{"issue":"6185","key":"2019041122190634300_B4","doi-asserted-by":"crossref","first-page":"1249783","DOI":"10.1126\/science.1249783","article-title":"Mechanism of activation of protein kinase JAK2 by the growth hormone receptor","volume":"344","author":"Brooks","year":"2014","journal-title":"Science"},{"issue":"5042","key":"2019041122190634300_B5","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1126\/science.1549776","article-title":"Human growth hormone and extracellular domain of its receptor: crystal structure of the complex","volume":"255","author":"de Vos","year":"1992","journal-title":"Science"},{"key":"2019041122190634300_B6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ghir.2015.06.001","article-title":"The growth hormone receptor","volume":"28","author":"Waters","year":"2016","journal-title":"Growth Horm IGF Res"},{"key":"2019041122190634300_B7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ygcen.2017.07.028","article-title":"The growth hormone signaling system: insights into coordinating the anabolic and catabolic actions of growth hormone","volume":"258","author":"Bergan-Roller","year":"2018","journal-title":"Gen Comp Endocrinol"},{"issue":"9","key":"2019041122190634300_B8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0898-6568(01)00186-3","article-title":"Signal transduction via the growth hormone receptor","volume":"13","author":"Zhu","year":"2001","journal-title":"Cell Signal"},{"issue":"4","key":"2019041122190634300_B9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/MED.0b013e328363183a","article-title":"Growth hormone and cancer: an update on progress","volume":"20","author":"Perry","year":"2013","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"2","key":"2019041122190634300_B10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/cphy.c150002","article-title":"Neuroendocrine regulation of growth hormone secretion","volume":"6","author":"Steyn","year":"2016","journal-title":"Compr Physiol"},{"key":"2019041122190634300_B11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.mce.2017.12.007","article-title":"Multiple signaling pathways convey central and peripheral signals to regulate pituitary function: lessons from human and non-human primate models","volume":"463","author":"V\u00e1zquez-Borrego","year":"2018","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"2019041122190634300_B12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000343995","article-title":"Insulin-like growth factor 2 in development and disease: a mini-review","volume":"59","author":"Bergman","year":"2013","journal-title":"Gerontology"},{"issue":"6","key":"2019041122190634300_B13","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.cmet.2016.05.014","article-title":"The somatotropic axis in human aging: framework for the current state of knowledge and future research","volume":"23","author":"Milman","year":"2016","journal-title":"Cell Metab"},{"issue":"1","key":"2019041122190634300_B14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1210\/er.2006-0001","article-title":"The role of the IGF system in cancer growth and metastasis: overview and recent insights","volume":"28","author":"Samani","year":"2007","journal-title":"Endocr Rev"},{"issue":"1","key":"2019041122190634300_B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00592-010-0227-z","article-title":"The IGF system","volume":"48","author":"Annunziata","year":"2011","journal-title":"Acta Diabetol"},{"key":"2019041122190634300_B16","doi-asserted-by":"crossref","first-page":"538019","DOI":"10.1155\/2015\/538019","article-title":"Insulin-like growth factor system in cancer: novel targeted therapies","volume":"2015","author":"Brahmkhatri","year":"2015","journal-title":"BioMed Res Int"},{"key":"2019041122190634300_B17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fendo.2015.00077","article-title":"The role of the insulin\/IGF system in cancer: lessons learned from clinical trials and the energy balance-cancer link","volume":"6","author":"Bowers","year":"2015","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2019041122190634300_B18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ecl.2012.04.014","article-title":"The insulin-like growth factor system in cancer","volume":"41","author":"Weroha","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"2019041122190634300_B19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1210\/edrv.22.1.0419","article-title":"The somatomedin hypothesis: 2001","volume":"22","author":"Le Roith","year":"2001","journal-title":"Endocr Rev"},{"issue":"6","key":"2019041122190634300_B20","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nrendo.2013.67","article-title":"The GH\/IGF-1 axis in ageing and longevity","volume":"9","author":"Junnila","year":"2013","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2019041122190634300_B21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11357-017-9966-x","article-title":"The GH\/IGF-1 axis in a critical period early in life determines cellular DNA repair capacity by altering transcriptional regulation of DNA repair-related genes: implications for the developmental origins of cancer","volume":"39","author":"Podlutsky","year":"2017","journal-title":"Geroscience"},{"issue":"13","key":"2019041122190634300_B22","doi-asserted-by":"crossref","first-page":"21579","DOI":"10.18632\/oncotarget.15375","article-title":"Targeting growth hormone receptor in human melanoma cells attenuates tumor progression and epithelial mesenchymal transition via suppression of multiple oncogenic pathways","volume":"8","author":"Basu","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"2019041122190634300_B23","first-page":"414","article-title":"Growth hormone, insulin-like growth factor system and carcinogenesis","volume":"67","author":"Boguszewski","year":"2016","journal-title":"Endokrynol Pol"},{"issue":"10","key":"2019041122190634300_B24","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1210\/jc.2017-01000","article-title":"Growth hormone and the epithelial-to-mesenchymal transition","volume":"102","author":"Brittain","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2019041122190634300_B25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrendo.2010.123","article-title":"The growth hormone receptor: mechanism of activation and clinical implications","volume":"6","author":"Brooks","year":"2010","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"2019041122190634300_B26","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tem.2017.05.003","article-title":"Tumour-derived human growth hormone as a therapeutic target in oncology","volume":"28","author":"Perry","year":"2017","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"2019041122190634300_B27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ncpendmet0677","article-title":"Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer","volume":"4","author":"Schally","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"1","key":"2019041122190634300_B28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1210\/er.2008-0022","article-title":"Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions","volume":"30","author":"Kleinberg","year":"2009","journal-title":"Endocr Rev"},{"issue":"6","key":"2019041122190634300_B29","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1210\/en.2016-1928","article-title":"Role of growth hormone in breast cancer","volume":"158","author":"Subramani","year":"2017","journal-title":"Endocrinology"},{"issue":"9","key":"2019041122190634300_B30","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1210\/en.2012-2208","article-title":"Growth hormone potentiates 17\u03b2-estradiol-dependent breast cancer cell proliferation independently of IGF-I receptor signaling","volume":"154","author":"Felice","year":"2013","journal-title":"Endocrinology"},{"issue":"10","key":"2019041122190634300_B31","doi-asserted-by":"crossref","first-page":"1010428317719121","DOI":"10.1177\/1010428317719121","article-title":"Influence of autocrine growth hormone on NF-\u03baB activation leading to epithelial-mesenchymal transition of mammary carcinoma","volume":"39","author":"Baskari","year":"2017","journal-title":"Tumour Biol"},{"issue":"5","key":"2019041122190634300_B32","doi-asserted-by":"crossref","first-page":"R155","DOI":"10.1530\/EJE-18-0018","article-title":"mechanisms in endocrinology: lessons from growth hormone receptor gene-disrupted mice: are there benefits of endocrine defects","volume":"178","author":"Basu","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2019041122190634300_B33","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.canlet.2015.05.031","article-title":"Autocrine human growth hormone stimulates the tumor initiating capacity and metastasis of estrogen receptor-negative mammary carcinoma cells","volume":"365","author":"Chen","year":"2015","journal-title":"Cancer Lett"},{"issue":"11","key":"2019041122190634300_B34","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1210\/me.2007-0092","article-title":"Autocrine growth hormone: effects on growth hormone receptor trafficking and signaling","volume":"21","author":"van den Eijnden","year":"2007","journal-title":"Mol Endocrinol"},{"issue":"4","key":"2019041122190634300_B35","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0002-9440(10)64071-0","article-title":"Growth hormone receptor is expressed in human breast cancer","volume":"158","author":"Gebre-Medhin","year":"2001","journal-title":"Am J Pathol"},{"issue":"10","key":"2019041122190634300_B36","doi-asserted-by":"crossref","first-page":"E1619","DOI":"10.1210\/jc.2011-1245","article-title":"Tumor expression of human growth hormone and human prolactin predict a worse survival outcome in patients with mammary or endometrial carcinoma","volume":"96","author":"Wu","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041122190634300_B37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4048\/jbc.2014.17.2.113","article-title":"Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status and a favorable prognosis in breast cancer","volume":"17","author":"Shin","year":"2014","journal-title":"J Breast Cancer"},{"issue":"11","key":"2019041122190634300_B38","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1158\/0008-5472.CAN-09-4502","article-title":"Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade","volume":"70","author":"Menashe","year":"2010","journal-title":"Cancer Res"},{"issue":"4","key":"2019041122190634300_B39","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1677\/ERC-08-0084","article-title":"Androgen receptor and growth factor signaling cross-talk in prostate cancer cells","volume":"15","author":"Zhu","year":"2008","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2019041122190634300_B40","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/jcb.24473","article-title":"Differential effects of exogenous and autocrine growth hormone on LNCaP prostate cancer cell proliferation and survival","volume":"114","author":"Nakonechnaya","year":"2013","journal-title":"J Cell Biochem"},{"issue":"2","key":"2019041122190634300_B41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/07435800.2014.966383","article-title":"Growth hormone enhances LNCaP prostate cancer cell motility","volume":"40","author":"Nakonechnaya","year":"2015","journal-title":"Endocr Res"},{"issue":"4","key":"2019041122190634300_B42","first-page":"1046","article-title":"Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma","volume":"75","author":"Cohen","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041122190634300_B43","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2605.2010.01064.x","article-title":"Growth hormone affects gene expression and proliferation in human prostate cancer cells","volume":"34","author":"Bidosee","year":"2011","journal-title":"Int J Androl"},{"issue":"7","key":"2019041122190634300_B44","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1210\/en.2016-1939","article-title":"Androgen receptor regulation of local growth hormone in prostate cancer cells","volume":"158","author":"Recouvreux","year":"2017","journal-title":"Endocrinology"},{"issue":"2","key":"2019041122190634300_B45","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1054\/ghir.2002.0271","article-title":"Co-expression of GH and GHR isoforms in prostate cancer cell lines","volume":"12","author":"Chopin","year":"2002","journal-title":"Growth Horm IGF Res"},{"issue":"1\u20132","key":"2019041122190634300_B46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10735-006-9027-8","article-title":"Co-expression of interleukin-6 and human growth hormone in apparently normal prostate biopsies that ultimately progress to prostate cancer using low pH, high temperature antigen retrieval","volume":"37","author":"Slater","year":"2006","journal-title":"J Mol Histol"},{"issue":"1\u20132","key":"2019041122190634300_B47","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.mce.2004.03.004","article-title":"Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells","volume":"220","author":"Weiss-Messer","year":"2004","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"2019041122190634300_B48","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1210\/en.2006-1761","article-title":"Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a\/b signaling pathway","volume":"148","author":"Dagvadorj","year":"2007","journal-title":"Endocrinology"},{"issue":"16","key":"2019041122190634300_B49","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1158\/1078-0432.CCR-05-0562","article-title":"Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence","volume":"11","author":"Li","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019041122190634300_B50","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1677\/ERC-09-0328","article-title":"Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo","volume":"17","author":"Gu","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2019041122190634300_B51","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1158\/0008-5472.CAN-07-2972","article-title":"Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells","volume":"68","author":"Tan","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"2019041122190634300_B52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/carcin\/bgt304","article-title":"SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer","volume":"35","author":"Iglesias-Gato","year":"2014","journal-title":"Carcinogenesis"},{"issue":"10","key":"2019041122190634300_B53","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1471-4914(01)02104-9","article-title":"The growth hormone\u2013insulin-like growth factor-I axis and colorectal cancer","volume":"7","author":"Bustin","year":"2001","journal-title":"Trends Mol Med"},{"issue":"7","key":"2019041122190634300_B54","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1007\/s13277-014-1845-9","article-title":"Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis","volume":"35","author":"Zoratto","year":"2014","journal-title":"Tumour Biol"},{"issue":"10","key":"2019041122190634300_B55","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00535-016-1181-5","article-title":"Carcinoma of the colon and rectum with deregulation of insulin-like growth factor 2 signaling: clinical and molecular implications","volume":"51","author":"Belharazem","year":"2016","journal-title":"J Gastroenterol"},{"issue":"5613","key":"2019041122190634300_B56","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1126\/science.1080902","article-title":"Loss of IGF2 imprinting: a potential marker of colorectal cancer risk","volume":"299","author":"Cui","year":"2003","journal-title":"Science"},{"issue":"23","key":"2019041122190634300_B57","doi-asserted-by":"crossref","first-page":"E3250","DOI":"10.1073\/pnas.1600561113","article-title":"Growth hormone is permissive for neoplastic colon growth","volume":"113","author":"Chesnokova","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"61","key":"2019041122190634300_B58","doi-asserted-by":"crossref","first-page":"103900","DOI":"10.18632\/oncotarget.21812","article-title":"Autocrine hGH stimulates oncogenicity, epithelial-mesenchymal transition and cancer stem cell-like behavior in human colorectal carcinoma","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"2019041122190634300_B59","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s10350-007-0258-x","article-title":"Insulin-like growth factor binding protein-3 inhibits colitis-induced carcinogenesis","volume":"50","author":"Belizon","year":"2007","journal-title":"Dis Colon Rectum"},{"issue":"6","key":"2019041122190634300_B60","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1101\/gr.5120106","article-title":"Variants in the GH-IGF axis confer susceptibility to lung cancer","volume":"16","author":"Rudd","year":"2006","journal-title":"Genome Res"},{"issue":"4","key":"2019041122190634300_B61","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/jjco\/hyn007","article-title":"Lung cancer risk associated with Thr495Pro polymorphism of GHR in Chinese population","volume":"38","author":"Cao","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"2019041122190634300_B62","doi-asserted-by":"crossref","first-page":"242151","DOI":"10.1155\/2009\/242151","article-title":"Chromosome 5p region SNPs are associated with risk of NSCLC among women","volume":"2009","author":"Van Dyke","year":"2009","journal-title":"J Cancer Epidemiol"},{"issue":"4","key":"2019041122190634300_B63","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/onc.2017.352","article-title":"A growth hormone receptor SNP promotes lung cancer by impairment of SOCS2-mediated degradation","volume":"37","author":"Chhabra","year":"2018","journal-title":"Oncogene"},{"issue":"48","key":"2019041122190634300_B64","doi-asserted-by":"crossref","first-page":"17424","DOI":"10.1073\/pnas.0506844102","article-title":"The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues","volume":"102","author":"Havt","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2019041122190634300_B65","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1002\/ijc.31308","article-title":"Inhibition of experimental small-cell and non-small-cell lung cancers by novel antagonists of growth hormone-releasing hormone","volume":"142","author":"Wang","year":"2018","journal-title":"Int J Cancer"},{"issue":"2\u20133","key":"2019041122190634300_B66","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12672-015-0217-2","article-title":"Expression of receptors for pituitary-type growth hormone-releasing hormone (pGHRH-R) in human papillary thyroid cancer cells: effects of GHRH antagonists on matrix metalloproteinase-2","volume":"6","author":"Catanuto","year":"2015","journal-title":"Horm Cancer"},{"issue":"5\u20136","key":"2019041122190634300_B67","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s12672-017-0307-4","article-title":"Inhibitory effects of antagonists of growth hormone-releasing hormone (GHRH) in thyroid cancer","volume":"8","author":"P\u00f3pulo","year":"2017","journal-title":"Horm Cancer"},{"issue":"24","key":"2019041122190634300_B68","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.2174\/092986705774454715","article-title":"The IGF-I\/IGF-I receptor pathway: implications in the pathophysiology of thyroid cancer","volume":"12","author":"Ciampolillo","year":"2005","journal-title":"Curr Med Chem"},{"issue":"3","key":"2019041122190634300_B69","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1210\/jc.2010-1255","article-title":"Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid","volume":"96","author":"Malaguarnera","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1\u20133","key":"2019041122190634300_B70","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.regpep.2007.12.008","article-title":"Expression of growth hormone-releasing hormone receptor splice variant 1 in primary human melanomas","volume":"147","author":"Chatzistamou","year":"2008","journal-title":"Regul Pept"},{"issue":"17","key":"2019041122190634300_B71","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.4161\/15384101.2015.945879","article-title":"Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function","volume":"13","author":"Szalontay","year":"2014","journal-title":"Cell Cycle"},{"issue":"1","key":"2019041122190634300_B72","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.bbrc.2013.10.023","article-title":"Human metastatic melanoma cell lines express high levels of growth hormone receptor and respond to GH treatment","volume":"441","author":"Sustarsic","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2019041122190634300_B73","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12672-017-0292-7","article-title":"Growth hormone receptor knockdown sensitizes human melanoma cells to chemotherapy by attenuating expression of ABC drug efflux pumps","volume":"8","author":"Basu","year":"2017","journal-title":"Horm Cancer"},{"issue":"10","key":"2019041122190634300_B74","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1038\/emm.2014.61","article-title":"Growth hormone receptor inhibition decreases the growth and metastasis of pancreatic ductal adenocarcinoma","volume":"46","author":"Subramani","year":"2014","journal-title":"Exp Mol Med"},{"issue":"6","key":"2019041122190634300_B75","doi-asserted-by":"crossref","first-page":"E1274","DOI":"10.3390\/ijms18061274","article-title":"Autocrine human growth hormone promotes invasive and cancer stem cell-like behavior of hepatocellular carcinoma cells by STAT3 dependent inhibition of CLAUDIN-1 expression","volume":"18","author":"Chen","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"20","key":"2019041122190634300_B76","doi-asserted-by":"crossref","first-page":"29465","DOI":"10.18632\/oncotarget.8781","article-title":"Human growth hormone and human prolactin function as autocrine\/paracrine promoters of progression of hepatocellular carcinoma","volume":"7","author":"Kong","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"2019041122190634300_B77","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/ng1295-447","article-title":"M6P\/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity","volume":"11","author":"De Souza","year":"1995","journal-title":"Nat Genet"},{"issue":"9","key":"2019041122190634300_B78","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1210\/en.2010-0273","article-title":"STAT3\u03b1 is oncogenic for endometrial carcinoma cells and mediates the oncogenic effects of autocrine human growth hormone","volume":"151","author":"Tang","year":"2010","journal-title":"Endocrinology"},{"issue":"5","key":"2019041122190634300_B79","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1530\/ERC-12-0042","article-title":"Autocrine human GH promotes radioresistance in mammary and endometrial carcinoma cells","volume":"19","author":"Bougen","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2019041122190634300_B80","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrendo.2010.171","article-title":"Growth hormone, the insulin-like growth factor axis, insulin and cancer risk","volume":"7","author":"Clayton","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"46","key":"2019041122190634300_B81","doi-asserted-by":"crossref","first-page":"81098","DOI":"10.18632\/oncotarget.19186","article-title":"Serum insulin-like growth factor-1 and its binding protein 3 as prognostic factors for the incidence, progression, and outcome of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2019041122190634300_B82","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1756-9966-28-89","article-title":"IGF-I and IGFBP-3 and the risk of lung cancer: a meta-analysis based on nested case-control studies","volume":"28","author":"Chen","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"2019041122190634300_B83","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1002\/ijc.28589","article-title":"Insulin-like growth factor I and risk of breast cancer by age and hormone receptor status\u2014a prospective study within the EPIC cohort","volume":"134","author":"Kaaks","year":"2014","journal-title":"Int J Cancer"},{"issue":"6","key":"2019041122190634300_B84","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1055-9965.EPI-13-1210-T","article-title":"Insulin-like growth factor-I and risk of differentiated thyroid carcinoma in the European prospective investigation into cancer and nutrition","volume":"23","author":"Schmidt","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"2019041122190634300_B85","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1158\/1055-9965.EPI-11-0179","article-title":"Concentrations of IGF-I and IGFBP-3 and brain tumor risk in the European Prospective Investigation into Cancer and Nutrition","volume":"20","author":"Rohrmann","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"2019041122190634300_B86","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ijc.30528","article-title":"Prediagnostic circulating concentrations of plasma insulin-like growth factor-I and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition","volume":"140","author":"Perez-Cornago","year":"2017","journal-title":"Int J Cancer"},{"issue":"1","key":"2019041122190634300_B87","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/bjc.2014.566","article-title":"Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort","volume":"112","author":"Ose","year":"2015","journal-title":"Br J Cancer"},{"issue":"1","key":"2019041122190634300_B88","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ijc.28342","article-title":"Prediagnostic plasma testosterone, sex hormone-binding globulin, IGF-I and hepatocellular carcinoma: etiological factors or risk markers","volume":"134","author":"Lukanova","year":"2014","journal-title":"Int J Cancer"},{"issue":"5","key":"2019041122190634300_B89","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/bjc.2012.19","article-title":"Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition","volume":"106","author":"Rohrmann","year":"2012","journal-title":"Br J Cancer"},{"issue":"10","key":"2019041122190634300_B90","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1158\/1055-9965.EPI-04-0874","article-title":"Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition Study","volume":"14","author":"Canzian","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"2019041122190634300_B91","first-page":"20596","article-title":"IGF-I CA19 repeat polymorphisms and cancer risk: a meta-analysis","volume":"8","author":"Guo","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"2","key":"2019041122190634300_B92","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s10549-017-4272-y","article-title":"Interaction of insulin-like growth factor-I and insulin resistance-related genetic variants with lifestyle factors on postmenopausal breast cancer risk","volume":"164","author":"Jung","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"2019041122190634300_B93","doi-asserted-by":"crossref","first-page":"e2578","DOI":"10.1371\/journal.pone.0002578","article-title":"IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3)","volume":"3","author":"Patel","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"2019041122190634300_B94","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12013-013-9784-4","article-title":"IGF1(CA)19 and IGFBP-3-202A\/C gene polymorphism and cancer risk: a meta-analysis","volume":"69","author":"Quan","year":"2014","journal-title":"Cell Biochem Biophys"},{"issue":"2","key":"2019041122190634300_B95","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/cncr.20375","article-title":"Genetic polymorphisms in the human growth hormone-1 gene (GH1) and the risk of breast carcinoma","volume":"101","author":"Ren","year":"2004","journal-title":"Cancer"},{"issue":"5","key":"2019041122190634300_B96","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1007\/s13277-013-1596-z","article-title":"GH1 T1663A polymorphism and cancer risk: a meta-analysis of case-control studies","volume":"35","author":"Shi","year":"2014","journal-title":"Tumour Biol"},{"issue":"2","key":"2019041122190634300_B97","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ijc.30439","article-title":"Energy restriction at young age, genetic variants in the insulin-like growth factor pathway and colorectal cancer risk in the Netherlands Cohort Study","volume":"140","author":"Simons","year":"2017","journal-title":"Int J Cancer"},{"issue":"3","key":"2019041122190634300_B98","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10549-006-9411-9","article-title":"The GH1\/IGF-1 axis polymorphisms and their impact on breast cancer development","volume":"104","author":"Wagner","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"2019041122190634300_B99","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.exger.2012.06.017","article-title":"Role of PAPP-A in aging and age-related disease","volume":"48","author":"Conover","year":"2013","journal-title":"Exp Gerontol"},{"issue":"1\u20132","key":"2019041122190634300_B100","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mce.2013.09.004","article-title":"Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications","volume":"386","author":"Kopchick","year":"2014","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"2019041122190634300_B101","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.critrevonc.2013.01.005","article-title":"The key role of growth hormone\u2013insulin\u2013IGF-1 signaling in aging and cancer","volume":"87","author":"Anisimov","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2019041122190634300_B102","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1447-0594.2009.00559.x","article-title":"Spontaneous dwarf rat: a novel model for aging research","volume":"10","author":"Kuramoto","year":"2010","journal-title":"Geriatr Gerontol Int"},{"issue":"10","key":"2019041122190634300_B103","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1210\/en.2007-0513","article-title":"Advanced rat mammary cancers are growth hormone dependent","volume":"148","author":"Shen","year":"2007","journal-title":"Endocrinology"},{"issue":"7","key":"2019041122190634300_B104","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1210\/en.2005-0058","article-title":"Adult-onset growth hormone and insulin-like growth factor I deficiency reduces neoplastic disease, modifies age-related pathology, and increases life span","volume":"146","author":"Sonntag","year":"2005","journal-title":"Endocrinology"},{"issue":"1","key":"2019041122190634300_B105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ghir.2006.10.007","article-title":"Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report","volume":"17","author":"Shevah","year":"2007","journal-title":"Growth Horm IGF Res"},{"issue":"4","key":"2019041122190634300_B106","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1530\/EJE-10-0859","article-title":"Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies","volume":"164","author":"Steuerman","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"2019041122190634300_B107","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ghir.2018.03.004","article-title":"Occurrence of neoplasms in individuals with congenital, severe GH deficiency from the Itabaianinha kindred","volume":"41","author":"Marinho","year":"2018","journal-title":"Growth Horm IGF Res"},{"issue":"2","key":"2019041122190634300_B108","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1530\/EJE-16-1047","article-title":"Mechanisms in endocrinology: the multiple facets of GHRH\/GH\/IGF-I axis: lessons from lifetime, untreated, isolated GH deficiency due to a GHRH receptor gene mutation","volume":"177","author":"Aguiar-Oliveira","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"8710","key":"2019041122190634300_B109","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0140-6736(90)91812-O","article-title":"Premature mortality due to cardiovascular disease in hypopituitarism","volume":"336","author":"Ros\u00e9n","year":"1990","journal-title":"Lancet"},{"issue":"3","key":"2019041122190634300_B110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1365-2265.1999.00650.x","article-title":"Life expectancy following surgery for pituitary tumours","volume":"50","author":"Bates","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2019041122190634300_B111","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1365-2265.1997.d01-1749.x","article-title":"Increased cerebrovascular mortality in patients with hypopituitarism","volume":"46","author":"B\u00fclow","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2019041122190634300_B112","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1530\/eje.0.1500149","article-title":"Direct causes of death in Japanese patients with hypopituitarism as analyzed from a nation-wide autopsy database","volume":"150","author":"Kaji","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2019041122190634300_B113","first-page":"1420","article-title":"Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality","volume":"85","author":"Nilsson","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041122190634300_B114","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1530\/EJE-07-0013","article-title":"Mortality and GH deficiency: a nationwide study","volume":"157","author":"Stochholm","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2019041122190634300_B115","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1210\/jc.2003-031601","article-title":"Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy","volume":"89","author":"Svensson","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"9254","key":"2019041122190634300_B116","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(00)04006-X","article-title":"Association between premature mortality and hypopituitarism","volume":"357","author":"Tomlinson","year":"2001","journal-title":"Lancet"},{"issue":"5","key":"2019041122190634300_B117","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1530\/EJE-13-0389","article-title":"GH therapy and cancer risk in hypopituitarism: what we know from human studies","volume":"169","author":"Pekic","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2019041122190634300_B118","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1210\/er.2009-0033","article-title":"Mortality in patients with pituitary disease","volume":"31","author":"Sherlock","year":"2010","journal-title":"Endocr Rev"},{"issue":"70","key":"2019041122190634300_B119","doi-asserted-by":"crossref","first-page":"70ra13","DOI":"10.1126\/scitranslmed.3001845","article-title":"Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans","volume":"3","author":"Guevara-Aguirre","year":"2011","journal-title":"Sci Transl Med"},{"issue":"2-3","key":"2019041122190634300_B120","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1054\/npep.2002.0889","article-title":"Consequences of growth hormone (GH) overexpression and GH resistance","volume":"36","author":"Bartke","year":"2002","journal-title":"Neuropeptides"},{"issue":"2","key":"2019041122190634300_B121","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1034\/j.1600-0676.2001.021002149.x","article-title":"Overexpressed growth hormone (GH) synergistically promotes carcinogen-initiated liver tumour growth by promoting cellular proliferation in emerging hepatocellular neoplasms in female and male GH-transgenic mice","volume":"21","author":"Snibson","year":"2001","journal-title":"Liver"},{"issue":"4","key":"2019041122190634300_B122","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000073704","article-title":"Can growth hormone (GH) accelerate aging? Evidence from GH-transgenic mice","volume":"78","author":"Bartke","year":"2003","journal-title":"Neuroendocrinology"},{"issue":"7","key":"2019041122190634300_B123","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1210\/jcem.86.7.7635","article-title":"Acromegaly and cancer: not a problem","volume":"86","author":"Melmed","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2019041122190634300_B124","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.4161\/cc.24026","article-title":"Hepatocellular alterations and dysregulation of oncogenic pathways in the liver of transgenic mice overexpressing growth hormone","volume":"12","author":"Miquet","year":"2013","journal-title":"Cell Cycle"},{"issue":"5","key":"2019041122190634300_B125","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/bjc.1995.484","article-title":"Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II)","volume":"72","author":"Bates","year":"1995","journal-title":"Br J Cancer"},{"issue":"3","key":"2019041122190634300_B126","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1096-6374(98)80110-X","article-title":"What is the function of IGF-II in postnatal life? Answers from transgenic mouse models","volume":"8","author":"Wolf","year":"1998","journal-title":"Growth Horm IGF Res"},{"issue":"9","key":"2019041122190634300_B127","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1158\/0008-5472.CAN-04-4602","article-title":"Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor","volume":"65","author":"Carboni","year":"2005","journal-title":"Cancer Res"},{"issue":"4","key":"2019041122190634300_B128","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10911-008-9097-1","article-title":"The impact of transgenic IGF-IR overexpression on mammary development and tumorigenesis","volume":"13","author":"Jones","year":"2008","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"4","key":"2019041122190634300_B129","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1535-6108(02)00055-7","article-title":"Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis","volume":"1","author":"Lopez","year":"2002","journal-title":"Cancer Cell"},{"issue":"58","key":"2019041122190634300_B130","doi-asserted-by":"crossref","first-page":"9359","DOI":"10.1038\/sj.onc.1208039","article-title":"Demonstration of tumor suppression by mannose 6-phosphate\/insulin-like growth factor 2 receptor","volume":"23","author":"Li","year":"2004","journal-title":"Oncogene"},{"issue":"11","key":"2019041122190634300_B131","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1210\/en.2002-220548","article-title":"Insulin-like growth factor-II\/mannose 6-phosphate receptor overexpression reduces growth of choriocarcinoma cells in vitro and in vivo","volume":"143","author":"O\u2019Gorman","year":"2002","journal-title":"Endocrinology"},{"issue":"3","key":"2019041122190634300_B132","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ghir.2005.04.001","article-title":"IGFBP-6 five years on; not so \u2018forgotten\u2019","volume":"15","author":"Bach","year":"2005","journal-title":"Growth Horm IGF Res"},{"issue":"6","key":"2019041122190634300_B133","first-page":"1317","article-title":"Biology of insulin-like growth factor binding protein-4 and its role in cancer (review)","volume":"28","author":"Durai","year":"2006","journal-title":"Int J Oncol"},{"issue":"5","key":"2019041122190634300_B134","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ghir.2014.04.007","article-title":"IGFBP-3: a cell fate pivot in cancer and disease","volume":"24","author":"Johnson","year":"2014","journal-title":"Growth Horm IGF Res"},{"issue":"3","key":"2019041122190634300_B135","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/mc.10105","article-title":"Insulin-like growth factor binding protein-1 over-expression in transgenic mice inhibits hepatic preneoplasia","volume":"36","author":"Lu","year":"2003","journal-title":"Mol Carcinog"},{"issue":"11","key":"2019041122190634300_B136","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/carcin\/bgn206","article-title":"Insulin-like growth factor-binding protein-5 (IGFBP-5) acts as a tumor suppressor by inhibiting angiogenesis","volume":"29","author":"Rho","year":"2008","journal-title":"Carcinogenesis"},{"issue":"3","key":"2019041122190634300_B137","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cytogfr.2014.12.001","article-title":"IGFBP-2: the dark horse in metabolism and cancer","volume":"26","author":"Russo","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"2019041122190634300_B138","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/1097-0142(195701\/02)10:1<100::AID-CNCR2820100113>3.0.CO;2-V","article-title":"Occurrence of cancer in acromegaly and in hypopituitarism","volume":"10","author":"Mustacchi","year":"1957","journal-title":"Cancer"},{"issue":"4","key":"2019041122190634300_B139","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1530\/EJE-16-0178","article-title":"Management of endocrine disease: acromegaly and cancer: an old debate revisited","volume":"175","author":"Boguszewski","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2019041122190634300_B140","first-page":"29","article-title":"The prevalence of benign and malignant neoplasms in acromegalic patients","volume":"61","author":"Ba\u0142dys-Walig\u00f3rska","year":"2010","journal-title":"Endokrynol Pol"},{"issue":"5","key":"2019041122190634300_B141","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1023\/A:1015713732717","article-title":"Acromegaly and cancer risk: a cohort study in Sweden and Denmark","volume":"13","author":"Baris","year":"2002","journal-title":"Cancer Causes Control"},{"issue":"8","key":"2019041122190634300_B142","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/archinte.1991.00400080113022","article-title":"Benign and malignant tumors in patients with acromegaly","volume":"151","author":"Barzilay","year":"1991","journal-title":"Arch Intern Med"},{"issue":"5","key":"2019041122190634300_B143","doi-asserted-by":"crossref","first-page":"e0127276","DOI":"10.1371\/journal.pone.0127276","article-title":"The role of diabetes in acromegaly associated neoplasia","volume":"10","author":"Cheng","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"2019041122190634300_B144","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1046\/j.1365-2265.1997.2561053.x","article-title":"Increased incidence of neoplasia in females with acromegaly","volume":"47","author":"Cheung","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2019041122190634300_B145","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11102-013-0501-5","article-title":"Increased thyroid cancer risk in acromegaly","volume":"17","author":"Dagdelen","year":"2014","journal-title":"Pituitary"},{"issue":"6","key":"2019041122190634300_B146","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1210\/jc.2017-02457","article-title":"Cancer incidence in patients with acromegaly: a cohort study and meta-analysis of the literature","volume":"103","author":"Dal","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041122190634300_B147","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s11102-010-0224-9","article-title":"Thyroid cancer is the most common cancer associated with acromegaly","volume":"13","author":"Gullu","year":"2010","journal-title":"Pituitary"},{"issue":"Suppl","key":"2019041122190634300_B148","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1507\/endocrj.47.SupplMarch_S57","article-title":"Incidence of malignant tumors in patients with acromegaly","volume":"47","author":"Higuchi","year":"2000","journal-title":"Endocr J"},{"issue":"2","key":"2019041122190634300_B149","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2265.2009.03619.x","article-title":"Increased cancer incidence in acromegaly\u2014a nationwide survey","volume":"72","author":"Kauppinen-M\u00e4kelin","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2019041122190634300_B150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1507\/endocrj.K07E-010","article-title":"The prevalence of benign and malignant tumors in patients with acromegaly at a single institute","volume":"55","author":"Kurimoto","year":"2008","journal-title":"Endocr J"},{"issue":"5","key":"2019041122190634300_B151","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/EJE-16-1064","article-title":"Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry","volume":"176","author":"Maione","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2019041122190634300_B152","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/jc.2014-2670","article-title":"Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic","volume":"99","author":"Mercado","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019041122190634300_B153","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1530\/eje.0.1510439","article-title":"Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA)","volume":"151","author":"Mestron","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2019041122190634300_B154","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2265.1987.tb00805.x","article-title":"Acromegaly","volume":"26","author":"Nabarro","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2019041122190634300_B155","first-page":"2730","article-title":"Mortality and cancer incidence in acromegaly: a retrospective cohort study","volume":"83","author":"Orme","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2019041122190634300_B156","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1210\/jc.2015-2372","article-title":"The incidence of cancer among acromegaly patients: results from the German Acromegaly Registry","volume":"100","author":"Petroff","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019041122190634300_B157","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2265.1998.00536.x","article-title":"Increased incidence of neoplasia in patients with pituitary adenomas","volume":"49","author":"Popovic","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2019041122190634300_B158","first-page":"55","article-title":"Ascertainment and natural history of treated acromegaly in Northern Ireland","volume":"59","author":"Ritchie","year":"1990","journal-title":"Ulster Med J"},{"issue":"8","key":"2019041122190634300_B159","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/1097-0142(19911015)68:8<1673::AID-CNCR2820680802>3.0.CO;2-0","article-title":"Acromegaly and gastrointestinal cancer","volume":"68","author":"Ron","year":"1991","journal-title":"Cancer"},{"issue":"9","key":"2019041122190634300_B160","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1530\/ERC-16-0553","article-title":"Acromegaly is associated with increased cancer risk: a survey in Italy","volume":"24","author":"Terzolo","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2019041122190634300_B161","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40618-016-0565-y","article-title":"Risk of malignant neoplasms in acromegaly: a case-control study","volume":"40","author":"Wolinski","year":"2017","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"2019041122190634300_B162","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1530\/ERC-17-0253","article-title":"Acromegaly at diagnosis in 3173 patients from the Li\u00e8ge Acromegaly Survey (LAS) Database","volume":"24","author":"Petrossians","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2019041122190634300_B163","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"issue":"4","key":"2019041122190634300_B164","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s11102-014-0586-5","article-title":"The role of colonoscopic screening in acromegaly revisited: review of current literature and practice guidelines","volume":"18","author":"Lois","year":"2015","journal-title":"Pituitary"},{"issue":"1","key":"2019041122190634300_B165","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11102-016-0744-z","article-title":"Complications of acromegaly: thyroid and colon","volume":"20","author":"Tirosh","year":"2017","journal-title":"Pituitary"},{"issue":"9","key":"2019041122190634300_B166","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2019041122190634300_B167","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/jc.2007-1191","article-title":"Mortality in acromegaly: a metaanalysis","volume":"93","author":"Dekkers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122190634300_B168","first-page":"166","article-title":"Excess mortality in acromegaly","volume":"68","author":"Holdaway","year":"2007","journal-title":"Horm Res"},{"issue":"2","key":"2019041122190634300_B169","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-08-0267","article-title":"A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly","volume":"159","author":"Holdaway","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2019041122190634300_B170","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1530\/ERC-16-0106","article-title":"Mortality in acromegaly: a 20-year follow-up study","volume":"23","author":"Ritvonen","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2019041122190634300_B171","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1530\/EJE-12-0084","article-title":"Predictors of morbidity and mortality in acromegaly: an Italian survey","volume":"167","author":"Arosio","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2019041122190634300_B172","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1530\/EJE-13-0166","article-title":"Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study","volume":"169","author":"Bogazzi","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2019041122190634300_B173","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1530\/EJE-13-1022","article-title":"Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy)","volume":"171","author":"Colao","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2019041122190634300_B174","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1530\/EJE-18-0015","article-title":"Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study","volume":"178","author":"Esposito","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2019041122190634300_B175","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1210\/jc.2009-1097","article-title":"ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly","volume":"94","author":"Sherlock","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041122190634300_B176","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11102-015-0700-3","article-title":"The role of cumulative growth hormone exposure in determining mortality and morbidity in acromegaly: a single centre study","volume":"19","author":"Varadhan","year":"2016","journal-title":"Pituitary"},{"issue":"6","key":"2019041122190634300_B177","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ghir.2010.09.003","article-title":"The role of insulin-like growth factor-1 and growth hormone in the mortality of patients with acromegaly after trans-sphenoidal surgery","volume":"20","author":"Wu","year":"2010","journal-title":"Growth Horm IGF Res"},{"issue":"1","key":"2019041122190634300_B178","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1530\/EJE-18-0255","article-title":"Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis","volume":"179","author":"Bolfi","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2019041122190634300_B179","first-page":"877","article-title":"Growth hormone treatment and leukemia","volume":"139","year":"1988","journal-title":"CMAJ"},{"key":"2019041122190634300_B180","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000182571","article-title":"Leukemia in growth-hormone-treated patients: an update, 1992","volume":"38","author":"Stahnke","year":"1992","journal-title":"Horm Res"},{"issue":"9","key":"2019041122190634300_B181","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1349-7006.1989.tb01721.x","article-title":"Risk factors for leukemia occurrence among growth hormone users","volume":"80","author":"Watanabe","year":"1989","journal-title":"Jpn J Cancer Res"},{"issue":"1 Pt 2","key":"2019041122190634300_B182","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0022-3476(97)70008-8","article-title":"Risk of leukemia in children treated with human growth hormone: review and reanalysis","volume":"131","author":"Allen","year":"1997","journal-title":"J Pediatr"},{"issue":"1","key":"2019041122190634300_B183","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1210\/jc.2009-0178","article-title":"Long-term safety of recombinant human growth hormone in children","volume":"95","author":"Bell","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"2019041122190634300_B184","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1001\/jama.1993.03510230067037","article-title":"Risk of leukemia after treatment with pituitary growth hormone","volume":"270","author":"Fradkin","year":"1993","journal-title":"JAMA"},{"key":"2019041122190634300_B185","first-page":"1035","article-title":"Growth hormone safety update from the National Cooperative Growth Study","volume":"13","author":"Maneatis","year":"2000","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"6","key":"2019041122190634300_B186","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1210\/jcem.84.6.5716","article-title":"Recent status in the occurrence of leukemia in growth hormone-treated patients in Japan. GH Treatment Study Committee of the Foundation for Growth Science, Japan","volume":"84","author":"Nishi","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019041122190634300_B187","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/archpedi.1985.02140060029020","article-title":"Growth hormone therapy and tumor recurrence. Findings in children with brain neoplasms and hypopituitarism","volume":"139","author":"Arslanian","year":"1985","journal-title":"Am J Dis Child"},{"issue":"8535","key":"2019041122190634300_B188","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0140-6736(87)90355-2","article-title":"Does growth hormone cause relapse of brain tumours","volume":"1","author":"Clayton","year":"1987","journal-title":"Lancet"},{"issue":"6","key":"2019041122190634300_B189","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1210\/jc.2013-4159","article-title":"Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study","volume":"99","author":"Patterson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2019041122190634300_B190","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1515\/jpem.2010.150","article-title":"Growth hormone therapy and the risk of tumor recurrence after brain tumor treatment in children","volume":"23","author":"Rohrer","year":"2010","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"7","key":"2019041122190634300_B191","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1210\/jcem.87.7.8606","article-title":"Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study","volume":"87","author":"Sklar","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2019041122190634300_B192","first-page":"4444","article-title":"Growth hormone treatment of children with brain tumors and risk of tumor recurrence","volume":"85","author":"Swerdlow","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019041122190634300_B193","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/cen.13502","article-title":"Long-term safety of growth hormone\u2014a combined registry analysis","volume":"88","author":"Stochholm","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2019041122190634300_B194","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/cen.13131","article-title":"Mortality and cancer incidence among patients treated with recombinant growth hormone during childhood in Israel","volume":"85","author":"Libruder","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2019041122190634300_B195","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s10072-015-2269-z","article-title":"Growth hormone therapy and risk of recurrence\/progression in intracranial tumors: a meta-analysis","volume":"36","author":"Shen","year":"2015","journal-title":"Neurol Sci"},{"issue":"12","key":"2019041122190634300_B196","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.jocn.2014.04.016","article-title":"Growth hormone treatment and risk of recurrence or development of secondary neoplasms in survivors of pediatric brain tumors","volume":"21","author":"Wang","year":"2014","journal-title":"J Clin Neurosci"},{"key":"2019041122190634300_B197","author":"Alotaibi"},{"issue":"4","key":"2019041122190634300_B198","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ghir.2014.02.001","article-title":"Association between growth hormone therapy and mortality, cancer and cardiovascular risk: systematic review and meta-analysis","volume":"24","author":"Deodati","year":"2014","journal-title":"Growth Horm IGF Res"},{"issue":"3","key":"2019041122190634300_B199","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000435856","article-title":"Description of the SAGhE cohort: a large european study of mortality and cancer incidence risks after childhood treatment with recombinant growth hormone","volume":"84","author":"Swerdlow","year":"2015","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"2019041122190634300_B200","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1210\/jc.2011-1995","article-title":"Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study","volume":"97","author":"Carel","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041122190634300_B201","doi-asserted-by":"crossref","first-page":"E213","DOI":"10.1210\/jc.2011-2882","article-title":"Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study","volume":"97","author":"S\u00e4vendahl","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019041122190634300_B202","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1210\/jc.2016-2046","article-title":"Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study","volume":"102","author":"Swerdlow","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019041122190634300_B203","first-page":"185","article-title":"Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS\/MAPK pathway","volume":"71","author":"Jorge","year":"2009","journal-title":"Horm Res"},{"issue":"8","key":"2019041122190634300_B204","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/bjc.2015.75","article-title":"Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes","volume":"112","author":"Kratz","year":"2015","journal-title":"Br J Cancer"},{"issue":"1","key":"2019041122190634300_B205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.a.36793","article-title":"Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues","volume":"167A","author":"Rauen","year":"2015","journal-title":"Am J Med Genet A"},{"issue":"3","key":"2019041122190634300_B206","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.gde.2009.04.001","article-title":"The RASopathies: developmental syndromes of Ras\/MAPK pathway dysregulation","volume":"19","author":"Tidyman","year":"2009","journal-title":"Curr Opin Genet Dev"},{"issue":"12","key":"2019041122190634300_B207","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1158\/1078-0432.CCR-17-0631","article-title":"Recommendations for cancer surveillance in individuals with RASopathies and other rare genetic conditions with increased cancer risk","volume":"23","author":"Villani","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019041122190634300_B208","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/ejhg.2011.37","article-title":"Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation","volume":"19","author":"Jongmans","year":"2011","journal-title":"Eur J Hum Genet"},{"issue":"9863","key":"2019041122190634300_B209","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(12)61023-X","article-title":"Noonan syndrome","volume":"381","author":"Roberts","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"2019041122190634300_B210","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000479107","article-title":"Occurrence of cranial neoplasms in pediatric patients with Noonan syndrome receiving growth hormone: is screening with brain MRI prior to initiation of growth hormone indicated","volume":"88","author":"Bangalore Krishna","year":"2017","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"2019041122190634300_B211","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ajmg.a.37379","article-title":"Occurrence of DNET and other brain tumors in Noonan syndrome warrants caution with growth hormone therapy","volume":"170A","author":"McWilliams","year":"2016","journal-title":"Am J Med Genet A"},{"issue":"3","key":"2019041122190634300_B212","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1210\/jc.2014-4357","article-title":"Endocrine disorders in Fanconi anemia: recommendations for screening and treatment","volume":"100","author":"Petryk","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122190634300_B213","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.4103\/2230-8210.145079","article-title":"Linear growth and endocrine function in children with ataxia telangiectasia","volume":"18","author":"Ehlayel","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"2019041122190634300_B214","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000452082","article-title":"Bloom\u2019s syndrome: clinical spectrum, molecular pathogenesis, and cancer predisposition","volume":"8","author":"Cunniff","year":"2017","journal-title":"Mol Syndromol"},{"issue":"5","key":"2019041122190634300_B215","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.canep.2014.07.006","article-title":"Epidemiology of childhood leukemia in the presence and absence of Down syndrome","volume":"38","author":"Mezei","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"2019041122190634300_B216","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.lfs.2017.12.035","article-title":"Actual state of knowledge in the field of diseases related with defective nucleotide excision repair","volume":"195","author":"Bukowska","year":"2018","journal-title":"Life Sci"},{"issue":"6","key":"2019041122190634300_B217","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ajmg.a.33711","article-title":"Cancer predisposition in children with Kabuki syndrome","volume":"155A","author":"Casanova","year":"2011","journal-title":"Am J Med Genet A"},{"issue":"2","key":"2019041122190634300_B218","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/path.2538","article-title":"High frequency of tumours in Mulibrey nanism","volume":"218","author":"Karlberg","year":"2009","journal-title":"J Pathol"},{"issue":"6","key":"2019041122190634300_B219","doi-asserted-by":"crossref","first-page":"e98686","DOI":"10.1371\/journal.pone.0098686","article-title":"Dubowitz syndrome is a complex comprised of multiple, genetically distinct and phenotypically overlapping disorders","volume":"9","author":"Stewart","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"2019041122190634300_B220","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/jmg.33.2.153","article-title":"Nijmegen breakage syndrome","volume":"33","author":"van der Burgt","year":"1996","journal-title":"J Med Genet"},{"issue":"3","key":"2019041122190634300_B221","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1053\/beha.2001.0158","article-title":"Chromosome instability syndromes","volume":"14","author":"Taylor","year":"2001","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"2019041122190634300_B222","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/MCD.0b013e3283557231","article-title":"Patient with a neurofibromatosis type 1 mutation but a clinical diagnosis of Noonan syndrome","volume":"21","author":"Croonen","year":"2012","journal-title":"Clin Dysmorphol"},{"issue":"10","key":"2019041122190634300_B223","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1210\/jc.2013-2491","article-title":"Bloom syndrome in short children born small for gestational age: a challenging diagnosis","volume":"98","author":"Renes","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2019041122190634300_B224","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1210\/jc.2015-1002","article-title":"Risk of neoplasia in pediatric patients receiving growth hormone therapy\u2014a report from the Pediatric Endocrine Society Drug and Therapeutics Committee","volume":"100","author":"Raman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041122190634300_B225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-15-0873","article-title":"GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults","volume":"174","author":"Allen","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2019041122190634300_B226","doi-asserted-by":"crossref","first-page":"e27095","DOI":"10.1002\/pbc.27095","article-title":"Meta-analysis of the incidence and patterns of second neoplasms after photon craniospinal irradiation in children with medulloblastoma","volume":"65","author":"Bavle","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2019041122190634300_B227","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.semradonc.2009.09.002","article-title":"Secondary malignancies across the age spectrum","volume":"20","author":"Ng","year":"2010","journal-title":"Semin Radiat Oncol"},{"key":"2019041122190634300_B228","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.12688\/f1000research.12057.1","article-title":"Update on GH therapy in adults","volume":"6","author":"Boguszewski","year":"2017","journal-title":"F1000 Res"},{"issue":"6","key":"2019041122190634300_B229","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1210\/jc.2011-0179","article-title":"Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Molitch","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041122190634300_B230","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-11-0286","article-title":"Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study","volume":"165","author":"Child","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2019041122190634300_B231","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/jc.2017-01899","article-title":"New neoplasm during GH replacement in adults with pituitary deficiency following malignancy: a KIMS analysis","volume":"103","author":"Krzyzanowska-Mittermayer","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019041122190634300_B232","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1210\/jc.2012-4059","article-title":"Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality","volume":"98","author":"Burman","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2019041122190634300_B233","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1210\/jc.2011-1215","article-title":"Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in Adults","volume":"96","author":"van Bunderen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019041122190634300_B234","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ghir.2015.06.006","article-title":"Reviewing the safety of GH replacement therapy in adults","volume":"25","author":"Stochholm","year":"2015","journal-title":"Growth Horm IGF Res"},{"issue":"2","key":"2019041122190634300_B235","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12020-016-1156-6","article-title":"The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer, and stroke","volume":"56","author":"Jasim","year":"2017","journal-title":"Endocrine"},{"issue":"49","key":"2019041122190634300_B236","doi-asserted-by":"crossref","first-page":"81862","DOI":"10.18632\/oncotarget.13251","article-title":"Growth hormone replacement therapy reduces risk of cancer in adult with growth hormone deficiency: a meta-analysis","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"2019041122190634300_B237","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.peptides.2017.01.009","article-title":"Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth","volume":"89","author":"Zarandi","year":"2017","journal-title":"Peptides"},{"issue":"1","key":"2019041122190634300_B238","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.canlet.2016.05.031","article-title":"Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model","volume":"379","author":"Evans","year":"2016","journal-title":"Cancer Lett"},{"issue":"6","key":"2019041122190634300_B239","first-page":"9559","article-title":"Inhibition of growth hormone receptor by Somavert reduces expression of GPER and prevents growth stimulation of triple-negative breast cancer by 17\u03b2-estradiol","volume":"15","author":"Girgert","year":"2018","journal-title":"Oncol Lett"},{"issue":"6","key":"2019041122190634300_B240","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.3892\/ol.2015.3770","article-title":"Effect of combination therapy of siRNA targeting growth hormone receptor and 5-fluorouracil in hepatic metastasis of colon cancer","volume":"10","author":"Zhou","year":"2015","journal-title":"Oncol Lett"},{"issue":"5","key":"2019041122190634300_B241","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1210\/er.2017-00073","article-title":"Insulin receptor isoforms in physiology and disease: an updated view","volume":"38","author":"Belfiore","year":"2017","journal-title":"Endocr Rev"},{"key":"2019041122190634300_B242","author":"Ekyalongo"},{"issue":"7","key":"2019041122190634300_B243","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1210\/en.2011-0231","article-title":"Minireview: IGF, insulin, and cancer","volume":"152","author":"Gallagher","year":"2011","journal-title":"Endocrinology"},{"issue":"3","key":"2019041122190634300_B244","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrc3215","article-title":"The insulin and insulin-like growth factor receptor family in neoplasia: an update","volume":"12","author":"Pollak","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2019041122190634300_B245","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1158\/1078-0432.CCR-13-1869","article-title":"Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer","volume":"20","author":"de Bono","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019041122190634300_B246","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/annonc\/mdu517","article-title":"Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer","volume":"26","author":"Scagliotti","year":"2015","journal-title":"Ann Oncol"},{"issue":"20 Pt 1","key":"2019041122190634300_B247","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1158\/1078-0432.CCR-06-0443","article-title":"Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors","volume":"12","author":"Wu","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019041122190634300_B248","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1158\/0008-5472.CAN-10-2274","article-title":"Dual IGF-I\/II\u2013neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth","volume":"71","author":"Gao","year":"2011","journal-title":"Cancer Res"},{"issue":"1","key":"2019041122190634300_B249","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s10637-014-0170-x","article-title":"Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I\/II neutralizing antibody, in Japanese patients with advanced solid tumours","volume":"33","author":"Iguchi","year":"2015","journal-title":"Invest New Drugs"},{"issue":"4","key":"2019041122190634300_B250","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/1535-7163.MCT-14-0751","article-title":"The IGF-Trap: novel inhibitor of carcinoma growth and metastasis","volume":"14","author":"Wang","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"2019041122190634300_B251","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/1535-7163.MCT-14-0144","article-title":"MEDI-573, alone or in combination with mammalian target of rapamycin inhibitors, targets the insulin-like growth factor pathway in sarcomas","volume":"13","author":"Zhong","year":"2014","journal-title":"Mol Cancer Ther"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/edrv\/article-pdf\/40\/2\/558\/28072881\/er.2018-00166.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T12:32:19Z","timestamp":1555072339000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/40\/2\/558\/5214057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":251,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,11,30]]},"published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/er.2018-00166","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2018,11,30]]}}}